Cure8 trial brief
Long-term registry data can provide real-world information about the safety and durability of adalimumab for people with moderately to severely active ulcerative colitis. Patients already on or considering adalimumab may find this data relevant to long-term treatment planning.
Adult patients with ulcerative colitis, clinicians treating UC, researchers studying long-term biologic safety and effectiveness, and patients currently on biologic therapy.
This is a registry (observational) study record of long-term safety and effectiveness monitoring for adalimumab (Humira) in adults with moderately to severely active ulcerative colitis. The registry enrolled patients already prescribed adalimumab or an immunomodulatory therapy and followed them for up to 10 years in routine clinical-practice settings.
The record lists planned enrollment (~8250), inclusion/exclusion criteria, and multiple U.S. clinical sites.
This ClinicalTrials.gov entry is a trial record for an observational registry sponsored by AbbVie; it reports planned design and eligibility rather than trial results. Registry follow-up was planned for 10 years. The entry does not itself provide outcomes or findings—look for published analyses or registry reports for results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...
Patients on anti-TNF biologics often seek safe ways to support gut microbial health. This trial tests a prebiotic supplement (2'-FL) for safety and whether it increases beneficial bacteria and butyrate in young people...
People with IBD sometimes are excluded from or uncertain about immune checkpoint inhibitor cancer trials because of concerns about triggering autoimmune flares. This trial explicitly studies safety and disease impact in...
